Go Pro
→ He bet half his $9 billion on ONE stock (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$128.82
+0.8%		$123.28
$77.58
▼
$135.05
$317.99B0.1910.78 million shs5.04 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-2.12%-2.40%-1.25%+12.81%+61.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$128.82
+0.8%		$123.28
$77.58
▼
$135.05
$317.99B0.1910.78 million shs5.04 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-2.12%-2.40%-1.25%+12.81%+61.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$134.504.41% Upside

Current Analyst Ratings Breakdown

Latest MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$140.00 ➝ $150.00
7/13/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$135.00 ➝ $140.00
7/13/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$135.00 ➝ $142.00
7/13/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$140.00 ➝ $145.00
7/9/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$112.00 ➝ $113.00
7/8/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$142.00
7/8/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$145.00 ➝ $150.00
7/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$120.00
6/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$130.00 ➝ $141.00
6/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Outperform$136.00 ➝ $155.00
(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.89$11.30 per share11.40$21.22 per share6.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5536.2713.255.1713.59%27.55%10.73%8/4/2026 (Estimated)

Latest MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.64%+5.75%95.77%14 Years

Latest MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.61%9/15/20269/15/202610/7/2026
5/26/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.96%6/15/20266/15/20267/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable

Recent News About These Companies

Merck (NYSE:MRK) posts better-than-expected sales in Q2 CY2026
 |  msn.comhttps://www.msn.com/en-us/money/topstocks/merck-nysemrk-posts-better-than-expected-sales-in-q2-cy2026/ar-AA29nwMl
Merck & Co., Inc. (NYSE:MRK) Releases Earnings Results, Beats Expectations By $0.13 EPS
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/merck-co-inc-nysemrk-releases-earnings-results-beats-expectations-by-013-eps-2026-08-04/
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
 |  zacks.comhttps://www.zacks.com/stock/news/2967587/compared-to-estimates-merck-mrk-q2-earnings-a-look-at-key-metrics?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm-2967587
Merck & Co., Inc. (NYSE:MRK) Updates FY 2026 Earnings Guidance
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/merck-co-inc-nysemrk-updates-fy-2026-earnings-guidance-2026-08-04/
Merck (MRK) Reports Q2 Loss, Beats Revenue Estimates
 |  zacks.comhttps://www.zacks.com/stock/news/2967238/merck-mrk-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2967238
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
August 4 at 7:00 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-co-inc-rahway-n-103000344.html
The Merck Product That Absolutely Demolished Wall Street's Forecasts
August 4 at 7:00 AM  |  finance.yahoo.comhttps://finance.yahoo.com/m/81d00451-1b9c-37ae-9f79-f6226ea5f551/the-merck-product-that.html
Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?
August 4 at 7:00 AM  |  barrons.comhttps://www.barrons.com/articles/merck-earnings-stock-price-54071b63
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
August 4 at 7:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20260804781126/en/Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Second-Quarter-2026-Financial-Results-Highlights-Key-Regulatory-and-Clinical-Milestones-Across-Broad-Diverse-Pipeline/
Merck posts better-than-expected second-quarter results on Keytruda strength
August 4 at 7:00 AM  |  reuters.comhttps://www.reuters.com/legal/litigation/merck-posts-better-than-expected-second-quarter-results-keytruda-strength-2026-08-04/
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line
August 4 at 6:41 AM  |  wsj.comhttps://www.wsj.com/business/earnings/merck-cuts-full-year-profit-forecast-as-acquisition-costs-weigh-on-bottom-line-2d8c24f2
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
August 4 at 6:34 AM  |  cnbc.comhttps://www.cnbc.com/2026/08/04/merck-mrk-earnings-q2-2026.html
Rathbones Group PLC Decreases Stock Holdings in Merck & Co., Inc. $MRK
August 4 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-rathbones-group-plc-decreases-stock-holdings-in-merck-co-inc-mrk-2026-08-04/
Agilent Technologies (A) Expands Its Oncology Diagnostics Reach—Can Growth Keep Up?
August 3 at 8:57 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/agilent-technologies-expands-oncology-diagnostics-211527726.html
$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off
August 3 at 8:57 PM  |  trefis.comT
Merck & Co., Inc. (MRK) Discusses HIV Program Updates and Phase III Data from International AIDS Conference Transcript
August 3 at 6:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4929499-merck-and-co-inc-mrk-discusses-hiv-program-updates-and-phase-iii-data-from-international-aids
Stock Market Today: Nasdaq Jumps 2%, Chevron Falls As Trump Lashes Out; This Viking Tops Entry (Live Coverage)
August 3 at 3:56 PM  |  finance.yahoo.comhttps://finance.yahoo.com/m/cdc87a38-f6bc-3590-b126-efc5dcd8debd/stock-market-today%3A-nasdaq.html
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity
August 3 at 2:00 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/merck-spotlights-weekly-hiv-treatment-monthly-prep-as-5b-growth-opportunity-2026-08-03/
Hamilton Wealth LLC Has $7.82 Million Holdings in Merck & Co., Inc. $MRK
August 3 at 6:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hamilton-wealth-llc-has-782-million-holdings-in-merck-co-inc-mrk-2026-08-03/
Merck & Co., Inc. $MRK Shares Sold by Pacer Advisors Inc.
August 3 at 6:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-shares-sold-by-pacer-advisors-inc-2026-08-03/
What To Expect From Merck’s (MRK) Q2 Earnings
August 3 at 5:56 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/expect-merck-mrk-q2-earnings-074922323.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$128.82 +1.05 (+0.82%)
As of 01:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas